Skip to content

key figures

About Servier

34th

largest pharmaceutical group worldwide

2nd

largest French pharmaceutical group

20%

Over 20% of revenue from brand-name medicines invested in R&D each year

70

Over 70 scientific partnerships and collaborations in 2021/2022

21,400

employees

97%

of the active ingredients used in the Group’s brand-name medicines are produced by Servier in France

29

international patient organizations collaborated with Servier in 2021/2022

Driving scientific and medical progress

4

therapeutic areas: oncology, cardiometabolism, neuroscience and immuno-inflammation

39

projects in clinical development (including 14 new molecular entities) and 29 research projects (May 2023)

4th

leading pharmaceutical group in cardiology worldwide

2nd

leading pharmaceutical group in hypertension worldwide

Global presence

150

Over 150 countries where the Group’s medicines are distributed

16

production sites

6

research centers

3

hubs (North and South America, Europe, Asia-Pacific) with 15 International Centers for Therapeutic Research

Social responsibility

25%

reduction in our greenhouse gas emissions between 2016 and 2030

40%

Target to appoint women to at least 40% of senior management positions within the Servier Group by 2024

4.23/5

Overall engagement score achieved by the Servier Group2

Financial performance

4.9

billion in revenue in 2021/2022

(including €3.7 billion for brand-name medicines and €1.2 billion for generic activities)

859

million in EBITDA in 2021/2022

[1] IQVIA, Analytics Link / World 74 countries – MAT Q1-2023
[2] Source: annual engagement survey conducted with the Gallup Institute – 2022 Group results